Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model

Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model

Abstract Background To compare the efficacy of low dose (27 mg) Bacillus Calmette-Guérin (BCG) and a full dose (81 mg) BCG immunotherapy for patients with intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) after a typical transurethral bladder resection. Methods We constructed a M...

Full description

Bibliographic Details
Main Authors: Zongren Wang, Han Xiao, Guangyan Wei, Ning Zhang, Mengchao Wei, Zebin Chen, Zhenwei Peng, Sui Peng, Shaopeng Qiu, Heping Li, Jianting Long
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Cancer
Subjects:
Bladder cancer
BCG
Intravesical therapy
Markov model
Online Access:http://link.springer.com/article/10.1186/s12885-018-4988-z

Internet

http://link.springer.com/article/10.1186/s12885-018-4988-z

Similar Items